UNSPSC 51285315: Nifurmazole

This classification denotes an anti-infective agent with the molecular formula C11H10N4O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) LOF2A7032C, chemically known as 3-(hydroxymethyl)-1-(3-(5-nitro-2-furyl)allylidenamino)-2,4-imidazolidindion but more generally known as nifurmazole, which bears US NIH Compound Identifier 72086. European Medicines Agency schedules Nifurmazole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09268MIG.

UNSPSC 51285315 Nifurmazole is a Commodity code that designates a specific antimicrobial pharmaceutical active ingredient, but state and local procurement activity under this code does not align with the nominal scope. The recent opportunities tagged to this code involve naloxone (an opioid-antagonist emergency medication) and safe drug deactivation systems, which fall outside nifurmazole's pharmaceutical classification. The source contains no recent solicitations for nifurmazole itself or vendors actively bidding on nifurmazole supply contracts to state and local jurisdictions.

The most recent tagged opportunity is Seminole County, Florida's IFB for naloxone and drug deactivation systems, posted June 30, 2026, with a response deadline of July 26, 2023 (a historical date inconsistent with the posting date). An earlier awarded contract from the Illinois Department of Public Health, completed August 28, 2026, supplied doxycycline hyclate and ciprofloxacin hydrochloride tablets through a piggyback arrangement with Chartwell Rx LLC under the MMCAP Infuse consortium, with a total award value of $2,999,999.11 over the contract life including renewals. Neither opportunity involves nifurmazole procurement. The code appears to see minimal or no current state and local demand, and the opportunities present in the dataset represent a data-tagging mismatch rather than active market activity for this specific pharmaceutical.